“We found sort of a special ‘flavor’ of CD4+ T cells critical for clearing this chronic virus replication,”
"These patients may be candidates in whom immunotherapy has the potential to show clinical benefit."
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Kelly Kersten, Ph.D., who joined Sanford Burnham Prebys this month as an assistant professor in the Cancer Metabolism and Microenvironment program, studies the interactions between immune cells and their microenvironment to better understand how they contribute to anti-tumor immune responses.
Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% compared to standard therapy. Despite these positive outcomes in event-free survival and overall survival, some patients did not respond well to therapy or relapsed quickly after treatment. Researchers wanted to assess if there were specific tumor characteristics associated with improved outcomes that could better inform treatment selection. Their findings were published today in Nature Medicine.
The award recognizes Dr. Chacon’s role as co-inventor of a licensed patent involving cancer immunotherapy.
By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.
Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from UCL.
Tuberculosis (TB) is the leading infectious killer worldwide, with 10.6 million cases and 1.6 million deaths in 2021 alone. One in five incident TB cases were attributable to malnutrition, more than double the number attributed to HIV/AIDS.
Two studies led by a researcher at UT Southwestern Medical Center show the effects of different SARS-CoV-2 variants on lung tissue, revealing what may cause some COVID-19 infections to be more severe than others.
Researchers from Osaka University find characteristic changes in CD4+ T cell categories and gene programs associated with autoimmune disease.
A new paper in Molecular Biology and Evolution, published by Oxford University Press, finds that HIV populations in people with higher viral loads also have higher rates of viral recombination.
Cedars-Sinai Cancer investigators have analyzed the cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with different responses to the treatment.
The body’s immune response to Epstein-Barr virus (EBV) may play a role in causing damage in people with multiple sclerosis, according to a new study led by UTHealth Houston.
Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency.
Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment, also finding a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.
In a scientific breakthrough that aids our understanding of the internal wiring of immune cells, researchers at Monash University in Australia have cracked the code behind IKAROS, an essential protein for immune cell development and protection against pathogens and cancer.
A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
A type of immune cell can help predict which patients may benefit most from cancer immunotherapies, researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute have found.
Novel insights from the pandemic may be propelling the field of immunology into a new golden age.
حدد الباحثون والمتعاونون في مايو كلينك بروتينًا تفرزه الخلايا المناعية والذي قد يقوم بدورٍ رئيسيٍ في ظهور مرضالتصلُّب الجانبي الضموري، المعروف أيضًا باسم مرض لو غيريغ. ووجد الفريق أيضًا أن العلاج التعديلي المناعي الذي يقوم بعملية إِحْصار للبروتين يمكنه استعادة الوظيفة الحركية في النماذج قبل السريرية. وتشير النتائج إلى أن البروتين، المعروف باسم أ5 إنتغرين (الذي يُنطق ألفا 5 إنتغرين)، هو مستهدف علاجي محتمل لعلاج مرض التصلُّب الجانبي الضموري.
Los investigadores y colaboradores de Mayo Clinic han identificado una proteína expresada en células inmunitarias que podría desempeñar un rol clave en el desarrollo de la esclerosis lateral amiotrófica (ELA), también conocida como enfermedad de Lou Gehrig. El equipo también descubrió que un tratamiento inmunomodulatorio que bloquea la proteína era capaz de restaurar la función motriz en modelos preclínicos. Los hallazgos indican que la proteína, conocida como integrina α5 (pronunciado integrina alfa 5), es un posible blanco terapéutico para la ELA.
Pesquisadores e colaboradores da Mayo Clinic identificaram uma proteína que é expressa por células imunológicas que pode desempenhar uma função importante no desenvolvimento daesclerose lateral amiotrófica (ELA), também conhecida como doença de Lou Gehrig. A equipe também descobriu que um tratamento imunomodulador que bloqueia a proteína conseguiu restaurar a função motora em modelos pré-clínicos. As descobertas sugerem que a proteína, conhecida como integrina α5 (pronunciada como integrina alfa 5), é um possível alvo terapêutico para ELA.
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
With the rise in machine learning applications and artificial intelligence, it's no wonder that more and more scientists and researchers are turning to supercomputers. Supercomputers are commonly used for making predictions with advanced modeling and simulations. This can be applied to climate research, weather forecasting, genomic sequencing, space exploration, aviation engineering and more.
The Cancer Research Institute and Lance Kawaguchi with the #SouthPoleTrek4Cancer ring in the Nasdaq Stock Market Closing Bell.
Researchers have found an inexpensive tool that may help reduce rates of pneumonia for hospitalized patients—and it comes with bristles on one end.
Researchers from the National University of Singapore (NUS) devise a simple and innovative way to directly identify and sort the immune cells involved in cell-mediated cytotoxicity.
Immune cells play an active and intimate role in directing the growth of human lung tissue during development, researchers find, revolutionising our understanding of early lung development and the role of immune cells outside of immunity.
UChicago Medicine researchers discover that restoring BAMBI to normal levels in immune suppressive cells can overcome resistance to radiation therapy.
Using lab-made cells, Harvard Med researchers identify how the immune system neutralizes herpesvirus. Study maps, for the first time, the maneuvers used by virus and host in the cell nucleus. Findings could inform design of new treatments for herpes and other viruses that replicate in the same way.
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.
By monitoring changes in circulating tumor DNA (ctDNA) among 30 patients treated with immunotherapies for metastatic non-small cell lung cancers, researchers were able to determine molecular response — the clearance of tumor genetic material in the bloodstream.
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.
Investigators from the C.S. Mott Center for Human Growth and Development at the Wayne State University School of Medicine reported today in a publication in Cancer Immunology Research the characterization of a novel therapeutic approach capable of restoring immune surveillance and providing long-term protection against ovarian cancer tumors.
A study led by researchers at Sylvester Comprehensive Cancer Center suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Downloadable video is available.
An international team of researchers from LMU and the Helmholtz Centre for Infection Research has visualized the structure of the so-called ASC speck.
One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory tract. But does that mean that it is no longer present in the body? To find out, a team from the Institut Pasteur specialized in HIV, in collaboration with a French public research institute, the Alternative Energies and Atomic Energy Commission (CEA), conducted a study on lung cells in an animal model.
According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.
Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumour in cancer patients who do not respond to any other current therapies.
Immune cells such as T and B cells are central to the body’s defence against both infections and tumours.
A special report published today in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.
Realizing the full potential of macrophage therapies relies on being able to see what these cellular allies are doing inside our bodies, and a team of Penn State researchers may have developed a way to watch them do their thing.
Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.
Researchers at the Francis Crick Institute, working with Imperial College London, King’s College London and University of Cambridge, have shown that an influx of water and ions into immune cells allows them to migrate to where they’re needed in the body.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
